Simpson Thacher Represents J.P. Morgan in Financing Arrangements in Connection with Boston Scientific’s Proposed Acquisition of the American Medical Systems Urology Portfolio of Endo International plc
04.28.15
This is only gets display when printing
Simpson Thacher recently represented J.P. Morgan Securities LLC, as the lead arranger, and JPMorgan Chase Bank, N.A., as administrative agent, in connection with a $750 million unsecured term loan facility for Boston Scientific Corporation (“Boston Scientific”), which will be used to fund Boston Scientific’s proposed acquisition of the American Medical Systems urology portfolio of Endo International plc. The acquisition is expected to close before the end of the third quarter of 2015, subject to receipt of applicable regulatory clearances and satisfaction of other customary conditions.
Simpson Thacher also recently represented J.P. Morgan Securities LLC, as the lead arranger, and JPMorgan Chase Bank, N.A., as administrative agent, in the refinancing of Boston Scientific’s existing $2 billion senior unsecured credit facility. Additionally, Simpson Thacher recently represented J.P. Morgan Securities LLC, as the lead arranger, and JPMorgan Chase Bank, N.A., as administrative agent, in connection with a $250 million unsecured revolving credit facility for Boston Scientific.
Boston Scientific, as a global medical technology leader for more than 35 years, advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
The Simpson Thacher team for the transaction included J.T. Knight, Mike Vernace and Hana Nah (Banking & Credit); Roxane Reardon, John Ericson and David Azarkh (Capital Markets); Joshua Levine, Abram Ellis and Christopher Hultman (Regulatory); Jodi Sackel (Tax); and Mark Chorazak (Bank Regulatory).